Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Zika Virus Infection and Thrombocytopenia Incidence

Open Forum Infect Dis; ePub 2018 Dec 3; Van Dyne, et al

Severe thrombocytopenia is a rare outcome of Zika virus (ZIKV) infection, although patients with thrombocytopenia and ZIKV experience prominent acute morbidity, according to a new study that examined the incidence and outcome of severe and non-severe thrombocytopenia and ZIKV in Puerto Rico during 2016. Severe thrombocytopenia was defined as platelet county <20 x 109/L, or platelet count <50 x 109/L and treatment for immune thrombocytopenia (ITP). Researchers found:

  • Of 37,878 patients with ZIKV infection, 47 (0.1%) had thrombocytopenia in the absence of an alternative etiology, including 12 with severe thrombocytopenia.
  • Most patients with thrombocytopenia were adult (77%) and male (53%).
  • Among patients with severe thrombocytopenia, all had bleeding, 33% were admitted to the ICU, and 8% died; 50% were treated for ITP.
  • Administration of ITP treatments in this patient population may be more efficacious than platelet transfusion in resolving thrombocytopenia.

Citation:

Van Dyne EA, Neaterour P, Rivera A, et al. Incidence and outcome of severe and non-severe thrombocytopenia associated with Zika virus infection—Puerto Rico, 2016. [Published online ahead of print December 3, 2018]. Open Forum Infect Dis. doi:10.1093/ofid/ofy325.